CommercialPrior AuthMedium impact
Symlin (pramlintide)
Blue Cross & Blue Shield of Mississippi·MS · Endocrinology, Family Medicine, Internal Medicine·Medical Policy
We identified it
Jun 20, 2026
Summary
BCBS Mississippi updated their Symlin (pramlintide) policy with revised prior authorization criteria for diabetes patients. Key changes include updated documentation requirements for type 1 or type 2 diabetes diagnosis, contraindications to therapy, and specific dose requirements for initial and renewal approvals.
Action Required
Immediately: Update prior authorization request procedures for Symlin (pramlintide) prescriptions. Ensure all requests include documentation of type 1 or type 2 diabetes diagnosis, contraindications assessment, and proper dosing (60 mcg for type 1, 120 mcg for type 2 diabetes). Verify patient age ≥15 years, endocrinologist consultation, failed glycemic control after 3+ months insulin use, and current prandial insulin therapy. Claims without proper documentation will be denied.